Main > > >FIBRILLATION. *

Cardio.>Arrhytmia. Atrial Fibrillation (AF). NonValvular AF (U)
(NVAF). Stroke/Systemic Embolism Risk Reduction:
Apixaban Tablets.
Oral Factor Xa Inhibitor AntiCoagulant.
EU Approval Date: 2012. 11.20.
USA Approval Date: 2013. 02.01.
(*) Companies; Patents; TradeMark & Web-Site Available on
Request.
UpDate: 2018. 01.29.




Cardio.>Arrhytmia. Atrial Fibrillation (AF). NonValvular AF (D)
(NVAF). Stroke/Systemic Embolism Risk Reduction:
Dabigatran Etexilate Capsules.
Oral Direct Thrombin Inhibitor AntiCoagulant
EU Approval Date : ?
USA Approval Date: 2010. 10.19.
Patent No. 01 Expiration Date: 2018. 02.18.
(*) Company; Patents; TradeMark & Web-Site Available on Request.
UpDate: 2018. 01.30.




Cardio.>Arrhytmia. Atrial Fibrillation (AF). NonValvular AF (D)
(NVAF). Stroke/Systemic Embolism Risk Reduction:
Dabigatran Etexilate Capsules.
Oral Direct Thrombin Inhibitor AntiCoagulant. REVERSAL: IdarucizuMAb
IV Injection 5 g.
USA Approval Date: 2015. 10.16.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 04.18.




Cardio.>Arrhytmia. Atrial Fibrillation (AF). NonValvular AF (D)
(NVAF). Stroke/Systemic Embolism Risk Reduction:
Rivaroxaban Tablets.
Xa Inhibitor.
EU Approval Date : 2011. 12.19.
USA Approval Date: 2012. 11.02.
(*) Companies; Patents; TradeMark & Web-Site Available on Request.
UpDate: 2018. 02.04.




Cardio.>Arrhytmia. Atrial Fibrillation (AF). NonValvular AF
(NVAF). Stroke/Systemic Embolism Risk Reduction:
Warfarin Sodium Tablets.
(*) Company : Bristol Myers Squibb.
Patent : Expired
TradeMark: Coumadin
Web-Site : www.coumadin.bmscustomerconnect.com
UpDate: 2018. 02.02.




Cardio.>Arrhytmia. Atrial Fibrillation (AF). Treat.: Vernakalant.HCl.
CA Approval Date: 2017. 03.14.
CA Launch Date : 2018. 10.24.
EU Approval Date: 2010. 09.
(*) Company; Patent & TradeMark Avai-
lable on Request.
UpDate: 2018. 10.25.











>FIBRILLATION. *'s products
This section has no products